Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia

作者：S. Kavanagh, V. Bril, J. Lipton · 发表于：Blood Research · 年份：2018 · DOI：10.5045/br.2018.53.2.172 · 被引用次数：10 · 研究领域：Medicine

REFERENCES 1. Sehn LH, Fenske TS, Laport GG. Follicular lymphoma: prognostic factors, conventional therapies, and hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012;18:S82-91. 2. Mi JQ, Li JM, Shen ZX, Chen SJ, Chen Z. How to manage acute promyelocytic leukemia. Leukemia 2012;26:1743-51. 3. Chang JE, Voorhees PM, Kolesar JM, et al. Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study. Hematol Oncol 2009;27:11-6. 4. Zhao H, Sun G, Kong D, et al. A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma. Med Oncol 2015;32:79. 5. Takahashi S. Combination therapy with arsenic trioxide for hematological malignancies. Anticancer Agents Med Chem 2010; 10:504-10. 6. Berenson JR, Matous J, Swift RA, Mapes R, Morrison B, Yeh HS. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res 2007;13:1762-8. 7. Gill H, Au WY, Cheung WW, Lee EY, Kwong YL. Oral arsenic trioxide-based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma. Ann Oncol 2014;25:1391-7. 8. Lo RK, Kwong YL. Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1. Ann Hematol 2014; 93:255-65. 9. Yoon JS, Hwang DW, Kim ES, et al. Anti-tumoral effect of arsenic compound, sodium metaarsenite (KML001), in non-Hodgkin's lymphoma: an in v...